1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow R1 Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia AP306 75 mg BID, AP306 125 mg BID, AP306 150 mg BID - Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis | Phase 2 | Recruiting | R1 Therapeutics | 168 | 2026-06-01 | 2026-08-26 |
China (1) · United States (1)